




WORLD BANK



ACEGID

*African Centre of Excellence for Genomics of Infectious Disease
Redeemer's University, Nigeria*

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)
REDEEMER'S UNIVERSITY**

**AUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 DECEMBER, 2016**

**BBC PROFESSIONALS
(Chartered Accountants)**

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)
REDEEMER'S UNIVERSITY**

**AUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 DECEMBER, 2016**

CONTENTS	PAGES
General Information	2
Report of the Center Officials	3
Report of the Independent Auditors	5
Income Statement	7
Statement of Financial Position	8
Statement of Cashflows	9
Notes to the Financial Statements	10
Statement of Value Added	14
Schedules to the Financial Statements	15

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)
REDEEMER'S UNIVERSITY**

AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER, 2016

GENERAL INFORMATION

PROJECT CENTER OFFICIALS

Prof Christain Happi	-	Center Director
Dr Folarin Onikepe	-	Deputy Director
Mr Adebayo Amao	-	Project Manager
Mr Afolabi Idowu	-	Project Accountant
Banjo Adeyemi A. (Mrs)	-	Project Internal Auditor
Osilaja Lucy O (Mrs)	-	Procurement Officer
Mr. Edevo Meshack	-	Finance Officer

DIRECTORATE OF INTERNAL AUDIT

Akinlawon O. Kikelomo (Mrs)	-	Principal Internal Auditor
-----------------------------	---	----------------------------

UNIVERSITY PRINCIPAL OFFICERS

Professor Z. Debo Adeyewa	-	Vice Chancellor
Professor Kayode S. Adekeye	-	Deputy Vice Chancellor
Mrs. Bolatito A. Oloketuyi	-	Registrar
Mr. Samuel A. Momodu	-	Ag. Bursar
Dr. Emmanuel L. Adebayo	-	University Librarian

INDEPENDENT AUDITORS

BBC Professionals
(Chartered Accountants)
CHARTER HOUSE
7 McNeil Road,
Sabo Yaba
Lagos

BANKERS

Diamond Bank Plc
Zenith Bank Plc

OPERATING OFFICE

Redeemers University
African Center of Excellence for
Genomics of Infectious Diseases (ACEGID)
P.M.B 230, Ede
Osun State

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Report of the Project Officials
for the year ended 31 December, 2016

The Centre is pleased to present their report together with the financial statements of the Project for the year ended 31 December, 2016.

1. **VISION**

To constitute a strong force in support of the research on the study of humans and microbes to transform the clinical care, surveillance and understanding of infectious diseases.

2. **PROJECT OBJECTIVES**

The objectives of the Project are as follows:

- a) To develop a critical mass of well-trained African genomics scientists;
- b) To empower African researchers to utilize genomics-based tools towards the control and elimination of infectious diseases;
- c) To create genomics curricula to support and promote cutting-edge genomics-based research;
- d) To engage communities in prevention efforts and public health education; and
- e) To contribute to the improvement of global public health and economic development.

3. **RESULT FOR THE YEAR**

	N
Income	1,026,735,355
Less: Expenditure	(436,083,575)
	<hr/>
Excess of income over expenditure	590,651,780
	=====

4. **EVENTS AFTER REPORTING PERIOD**

There are no material events after the reporting period that will affect these financial statements.

5. **EMPLOYMENT OF DISABLED PERSONS**

It is the center's policy that there should be no discrimination in considering applications for employment including those from disabled persons. All employees whether or not disabled are given equal opportunities to develop.

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Report of the Project Officials
for the year ended 31 December, 2016

6. PROJECT OFFICIALS

The project officials are responsible for the preparation of the financial statements which give a true and fair view of the state of affairs, and of the result for the year and in compliance with the International and Local Standard/Regulations.

They are obliged to ensure that:

- Proper accounting records are maintained;
- Internal control measures are instituted which, as far as is reasonably possible, safeguard the assets;
- Actions are taken to prevent and detect fraud and other irregularities;
- Applicable accounting standards are followed;
- Suitable accounting policies are adopted and consistently applied;
- Judgements and estimates made are reasonable and prudent, and
- The going-concern basis is used, unless it is inappropriate to presume that the center will continue in operation.

7. INDEPENDENT AUDITORS

Messrs BBC Professionals (Chartered Accountants) have indicated their willingness to continue in office. In accordance with Section 357(2) of the Companies and Allied Matters Act CAP C20 LFN 2004, the project officials are authorised to consider the re-appointment of the Auditors.

BY ORDER OF THE PROJECT OFFICIALS


Prof. Christian Happi
Center Director

Osun, Nigeria
14th June, 2017

**REPORT OF THE INDEPENDENT AUDITORS TO THE OFFICIALS OF
AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

We have audited the accompanying financial statements of African Center of Excellence for Genomics of Infectious Diseases (ACEGID) set out on pages 7 to 13 which comprise the Statement of Financial Position as at 31 December, 2016, the income statement and statement of cash flows for the year then ended, the summary of significant accounting policies and explanatory notes.

In our opinion, the financial statements give a true and fair view of the financial position of African Centre of Excellence for Genomics of Infectious Diseases (ACEGID) as at 31 December, 2016 and of its financial performance and cash flows for the year then ended in accordance with International Financial Reporting Standards and the requirements of the Companies and Allied Matters Act CAP C20 LFN 2004, and the Financial Reporting Council of Nigeria Act, 2011.

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Centre in accordance with the Institute of Chartered Accountants of Nigeria (ICAN) Professional Code of Conduct and Guide for Accountants, which is consistent with the International Ethics Standards Board for Accountants Code of Ethics for Professional Accountants (Part A and B), together with other ethical requirements that are relevant to our audit of the financial statements in Nigeria, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

The Project Officials are responsible for the other information. The other information refer to the Officials' Report as required by the Companies and Allied Matters Act CAP C20 LFN 2004, which we obtained prior to the date of this auditor's report. The other information does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Project Officials for the Financial Statements

The Project Officials are responsible for the preparation and fair presentation of the financial statements in accordance with International Financial Reporting Standards and the requirements of the Companies and Allied Matters Act CAP C20 LFN 2004, Financial Reporting Council of Nigeria Act No 6, 2011, and for such internal control as the Directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Directors are responsible for assessing the Centre's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Officials either intend to liquidate the Centre to cease operations, or have no realistic alternative but to do so.

Partners:J O Obogwu
E U Itodo A M Adetuyi
G C Egwuenu**BN: 133294**Other Offices in Nigeria:
Abuja Akure Benin-City
Ibadan Kaduna**PrimeGlobal**An Association of
Independent Accounting Firms

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Centre's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Centre Officials.
- Conclude on the appropriateness of the Officials' use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Centre's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Centre to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We also provided those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements


In accordance with the Sixth Schedule of Companies and Allied Matters Act CAP C20 LFN 2004, we expressly state that:

- i We have obtained all the information and explanation which to the best of our knowledge and believe were necessary for the purpose of our audit;
- ii The Centre has kept proper books of account, so far as appears from our examination of those books; and
- iii The Centre's statement of financial position and its income statement are in agreement with the books of account and returns.

Lagos, Nigeria

14 June, 2017




Everestus Itodo, FCA
FRC/2013/ICAN/00000002513

For: BBC PROFESSIONALS
Chartered Accountants

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Income Statement

For the year ended 31 December, 2016

	Notes	2 0 1 6 N	2 0 1 5 N
INCOME	5	1,026,735,355	147,172,706
EXPENDITURE:			
Salaries and wages		20,423,683	26,359,931
Advertisement and publicity		2,331,600	440,000
Seminars & courses		48,138,564	75,392,164
ACE meetings and workshop		14,744,812	4,138,500
Night allowance		-	1,109,065
Staff relocation expenses		-	1,851,800
Printing and stationery		434,320	12,200
Air fare		2,073,171	15,470,284
Honoraria		-	92,000
Internet connectivity		6,000	311,325
I.T expenses		621,850	131,900
Cleaning		784,402	35,000
Electricity & lighting		1,290,330	10,500
Telephone and postages		117,100	9,300
Transport		577,446	779,144
Entertainment		290,451	2,025,335
Bank charges		270,753	60,960
Hotel expenses		1,109,237	7,167,806
Repairs and maintenance		1,061,615	200,400
Motor vehicle running		1,371,393	237,942
Exchange difference		(50,555)	-
Lab consumables		2,172,862	17,291,081
Audit fees		500,000	500,000
Depreciation		5,835,338	2,091,761
H3 Africa expenses		319,092,059	-
NIH expenses		12,887,146	-
		436,083,575	155,718,398
Surplus/(deficit) transferred to Accumulated Fund	7	590,651,780	(8,545,692)

Note: The explanatory notes on pages 10 to 13 are to be read with these financial statements.

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Statement of Financial Position

As at 31 December, 2016

	Notes	2 0 1 6 N	2 0 1 5 N
ASSETS :			
NON-CURRENT ASSETS	4	184,027,911	10,148,598
CURRENT ASSETS			
Cash and Cash Equivalents	8	488,440,497	137,264,886
Other Receivables	9	17,987,750	-
NET ASSETS		<u>690,456,158</u>	<u>147,413,484</u>
FUND AND LIABILITY			
Accumulated fund	7	582,106,088	(8,545,692)
Payables	6	108,350,070	155,959,176
		<u>690,456,158</u>	<u>147,413,484</u>

Note: The explanatory notes on pages 10 to 13 are to be read with these financial statements.

The financial statements were approved by the Officials on 9 June, 2017 and signed on its behalf by:


Professor Christian Happi
Project Director


Mr Afolabi Idowu
Project Accountant

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Statement Of Cash Flows

For the year ended 31 December, 2016

	Notes	2 0 1 6 N	2 0 1 5 N
CASHFLOWS FROM OPERATING ACTIVITIES			
Excess of income over expenditure	7	590,651,780	(8,545,692)
Adjustments for non-cash items:			
Depreciation	4	5,835,338	2,091,761
Cashflow before changes in working capital		596,487,118	(6,453,931)
Changes in Working Capital			
Changes in payables	6	(47,609,106)	155,959,176
Changes in receivables	9	(17,987,750)	
INVESTING ACTIVITIES			
Purchase of Non-current Assets	4	(179,714,651)	(12,240,359)
Net increase in cash and cash equivalents		351,175,611	137,264,886
Cash and cash equivalents as at 1 January		137,264,886	-
Cash and cash equivalents as at 31 December	8	488,440,497	137,264,886
		=====	=====

Note: The explanatory notes on pages 10 to 13 are to be read with these financial statements.

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Notes to the financial statements

for the year ended 31 December, 2016

1. Reporting Entity

African Centre of Excellence For Genomics and Infectious Diseases (ACEGID) is an international capacity building project with Centres all over the West African countries :- Senegal, Sierra Leone, Nigeria etc and the headquarter is situated at Redeemers University, Ede in Osun State, Nigeria.

The mandate of this Centre primarily is to train Students on a regional basis and as well helps in infectious diseases diagnoses, its controls and preventions. However, an average of 23 PhD Students and 173 Masters Student are expected to be trained in the region. The Center has a live span of four years starting from year 2014 to year 2018.

2. Basis of presentation and compliance with IFRSs

The Centre's financial statements for the period ended 31 December, 2016 are financial statements prepared and presented in accordance with, and comply with International Financial Reporting Standard (IFRS) and International Financial Reporting Interpretation Committee (IFRIC) interpretations issued and effective for the period presented.

These financial statements comprise income statement, statement of financial position, the statement of cash flows, the accounting policies and the explanatory notes. The financial statements have been prepared in accordance with the going concern principle which is measured at fair value.

The financial statements are presented in Naira, which is the Center's presentational currency. The figures shown in the financial statements are stated to the nearest Naira.

The cash flows from operating, investing and financing activities are determined by using the indirect method.

3. Significant accounting policies

The accounting policies set out below have been applied in these financial statements unless otherwise indicated.

Basis of Accounting

The accounts are prepared under the historical cost convention.

Foreign Currencies

Account balances in foreign currencies are converted to Naira at the rates ruling at the Statement of financial position date.

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Notes to the financial statements

for the year ended 31 December, 2016

Non-Financial Assets

Non-Financial Assets are stated at cost or valuation less accumulated depreciation and will be tested for impairment in compliance with IFRS where there are indications to do so.

Depreciation

Depreciation is provided on the straight line basis at the following rates, calculated to write-off the cost of the assets over their estimated useful lives:

Land	0%
Buildings Improvement	10%
IT Equipment	12.5%
Furniture and Fittings	12.5%
Office Equipment	12.5%
Labouratory Equipment	12.5%
Guest House Equipment	12.5%

Impairment

Impairment test will be carried out on all non-financial assets subject to management discretion so as to ensure assets are not carried at more than their recoverable amount which is the higher of fair value less cost of disposal and value in use.

Payables

Payables are recognised at the completion of supplies, projects or jobs.

Taxation

The Centre is a non-profit making organisation, hence its not liable to taxation.

Investment Income

Interest income are accounted for in the year they are received.

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Notes to the financial statements
for the year ended 31 December, 2016

4. PROPERTY, PLANT AND EQUIPMENT

COST	BUILDING IMPROVEMENTS =N=	IT EQUIPMENT =N=	FURNITURE & FITTINGS =N=	OFFICE EQUIPMENT =N=	LABORATORY EQUIPMENT =N=	GUEST HOUSE EQUIPMENT =N=	TOTAL =N=
AT 1 JANUARY, 2016	494,750	258,661	4,174,100	404,400	6,908,448	-	12,240,359
ADDITIONS	17,055,270	2,707,715	6,999,900	9,765,320	141,762,306	1,424,140	179,714,651
AT 31 DECEMBER, 2016	17,550,020	2,966,376	11,174,000	10,169,720	148,670,754	1,424,140	191,955,010
DEPRECIATION							
TO 1 JANUARY, 2016	19,790	64,665	1,043,525	92,975	870,806	-	2,091,761
CHARGE FOR THE YEAR	1,755,002	370,797	1,396,750	1,271,215	863,556	178,018	5,835,338
TO 31 DECEMBER, 2016	1,774,792	435,462	2,440,275	1,364,190	1,734,362	178,018	7,927,099

NET BOOK VALUE

AT 31 DECEMBER, 2016	15,775,228	2,530,914	8,733,725	8,805,530	146,936,392	1,246,123	184,027,911
AT 31 DECEMBER, 2015	474,960	193,996	3,130,575	311,425	6,037,642	-	10,148,598

**AFRICAN CENTRE OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Notes to the financial statements

for the year ended 31 December, 2016

2 0 1 6

2 0 1 5

N

N

5. INCOME

Grant received from World Bank (Note 5.1)
Interest on bank accounts
Income from students tuition fees
Income from other funds (Note 5.2)

503,133,966
3,966,101
17,069,000
502,566,288

147,172,327
379
-
-

1,026,735,355
=====

147,172,706
=====

.1 The grant received from world bank totalling N503,133,966 was both in cash and through payment for Research Equipment.

.2 Income from other funds was received from NIH to support research on malaria and also from H3 Africa and JWARG to support general research on infectious diseases.

Funding from NIH
Funding from JWARG
Funding from H3 Africa

19,629,288
60,900,000
422,037,000

502,566,288
=====

6. PAYABLES

Accrued audit fees
Redeemers University
H3 Africa Project (Diamond Bank Dom)(\$15,057.67)
H3 Africa Project (Zenith Bank Naira)
H3 Africa Project (Zenith Bank Dom)(\$343,545.21)
Payables to Broad Institute(\$304,474.96)
Unremitted Withholding Taxes
Other Payables

500,000
10,608,991
30,620,963
-
66,450,939
-
167,577
1,600

108,350,070
=====

500,000
22,852,570
2,958,771
3,367,567
66,450,939
59,829,329
-
-

155,959,176
=====

7. ACCUMULATED FUND

At 1 January
Surplus/(deficit) for the year
At 31 December

(8,545,692)
590,651,780
582,106,088

582,106,088
=====

-
(8,545,692)
(8,545,692)

(8,545,692)
=====

8. CASH AND CASH EQUIVALENTS

Cash
Diamond Bank Current Account-NGN
Diamond Bank Current Account-Dom
Diamond Bank JWARG Account-Dom
Diamond Bank H3 Africa Account-Dom
Zenith Bank NIH Account-Dom

825,600
35,276,633
277,920,292
60,903,328
106,772,502
6,742,142

488,440,497
=====

-
137,167,113
97,773

137,264,886
=====

9. OTHER CURRENT ASSETS

Receivable from H3 Africa
Receivable from Redeemer's University Of Nigeria

918,750
17,069,000
17,987,750

17,987,750
=====

-
-
-

-
=====

10. CONTINGENT LIABILITIES

There were no known contingent liabilities in respect of legal actions against the Center for the period ended 31 December, 2016.

**AFRICAN CENTER OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Statement of Value Added

For the year ended 31 December, 2016

	2016		2015	
	N	%	N	%
Income	1,026,735,355		147,172,706	
Cost of materials and services	(409,824,554)		(127,266,706)	
Value Added	616,910,801	100	19,906,000	100
	=====	===	=====	===
Applied as follows:				
To pay employees				
Salaries and Wages	20,423,683	3	26,359,931	132
Future expansion				
Depreciation	5,835,338	1	2,091,761	11
Excess/(deficit) of income over expenditure	590,651,780	96	(8,545,692)	(43)
Value Added	616,910,801	100	19,906,000	100
	=====	===	=====	===

Value added shows the additional fund generated in the year by ACEGID to the Center through the efforts of the Trustees and Employees and how this new fund was distributed with portion retained in the Center for future development.

**AFRICAN CENTER OF EXCELLENCE FOR
GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

Schedules to the financial statements

For the year ended 31 December, 2016

LIST OF MATERIAL ASSETS

	=N=
1. BUILDINGIMPROVEMENT	
Labouratory renovation	10,441,030
Plumbing works	3,085,670
Electrical works	3,085,670
Partitioning with board and glass	592,250
Flowers and lawn	345,400
	17,550,020
	=====
2. FURNITURE, FITTINGS AND EQUIPMENT	
IT EQUIPMENT	
HP Desktop computer	115,000
Multi media Projector	1,637,950
Installation of CCTV camera	954,765
	2,707,715
	=====
3. FURNITURE AND FITTINGS	
Quarter window blinds	235,620
Cashier seats for labouratory	1,152,000
Office furniture	3,385,000
Cupboard, white board & notice board	95,000
Glass office tables	1,473,380
Labouratory chairs	178,900
Shelves	480,000
	6,999,900
	=====
4. OFFICE EQUIPMENT	
Thermocool chest freezer	69,900
Samsung refrigerator	95,000
1.5 HP panasonic split AC (28)	3,176,500
10KW/480 hybrid voltron inverter	3,000,000
Fridge	96,000
Installation of solar panel	3,129,500
Glass office tables	76,420
File cabinet	34,000
Rexel shredder	45,000
Thermocool Fridge HR - 107	45,000
	9,767,320
	=====
5. LAB EQUIPMENT	
Thermo scientific1284 biological safety cabinet	45,940,718
Mi Seq FGxTM sequencing system machine	95,821,588
	141,762,306
	=====